A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Stephen L. Chan; Martin Schüler; Yoon‐Koo Kang; Chia‐Jui Yen; Julien Edeline; Su Pin Choo; Chia‐Chi Lin; Takuji Okusaka; Karl-Heinz Weiss; Teresa Macarulla; Stéphane Cattan; Jean–Frédéric Blanc; Kyung-Hun Lee; Michela Maur; Shubham Pant; Masatoshi Kudo; Éric Assenat; Andrew X. Zhu; Thomas Yau; Ho Yeong Lim; Jordi Bruix; Andreas Geier; Carmen Guillén‐Ponce; Angelica Fasolo; Richard S. Finn; Jia Fan; Arndt Vogel; Shukui Qin; Markus Riester; Vasiliki Katsanou; Monica Chaudhari; Tomoyuki Kakizume; Yi Gu; Diana Graus Porta; Andrea P. Myers; Jean‐Pierre Delord

doi:10.1186/s13046-022-02383-5

Related publications

Article2019

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

Funda Meric‐Bernstam, Shahneen Sandhu, Omid Hamid, Anna Spreafico, Stefan Kasper, Reinhard Dummer, Toshio Shimizu, Neeltje Steeghs, Nancy Lewis, C. Talluto, Sinead Dolan, Andrew Bean, Robert J. Brown, Damian Trujillo, Nitya Nair, Jason J. Luke

Article2009

First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors

Shahneen Sandhu, Peter C.C. Fong, Sophia Frentzas, Amita Patnaik, K. Papadopoulos, Brenda Tromp, Thomas A. Puchalski, Birge Berns, Anthony W. Tolcher, Johann S. de Bono

Article2016

Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).

Ghassan K. Abou‐Alfa, Bruno Sangro, Michael A. Morse, Andrew X. Zhu, Richard D. Kim, Ann‐Lii Cheng, Masatoshi Kudo, Yoon‐Koo Kang, Stephen L. Chan, Joyce Antal, Jillian Boice, Feng Xiao, Shannon R. Morris, Johanna C. Bendell

Article2022

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Funda Meric‐Bernstam, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc R. Pelletier, Shahneen Sandhu

Article2013

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Shahneen Sandhu, K. Papadopoulos, Peter C.C. Fong, Amita Patnaik, Christina Messiou, David Olmos, George Wang, Brenda Tromp, Thomas A. Puchalski, Frances R. Balkwill, Birge Berns, Shobha Seetharam, Johann S. de Bono, Anthony W. Tolcher